EZH2:癌症研究中的一个关键的竞争性内源性RNA-一个范围审查
Sadra Salehi-Mazandarani1, Sharareh Mahmoudian-Hamedani1, Ziba Farajzadegan2
1Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Advanced biomedical research
|June 16, 2025
概括
竞争的内源RNAs (ceRNAs) 调节癌症中的增强性-2多抑制复合体2亚单元 (EZH2). 本综述确定了66个涉及EZH2的ceRNA轴,突出了它们在癌症治疗中的治疗潜力.
科学领域:
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
- 在瘤学瘤学.
背景情况:
- 竞争的内源RNAs (ceRNAs) 是癌症进展的关键调节者.
- 增强体2多组复合抑制复合体2亚单元 (EZH2) 的增强体作为一个在癌症中具有双重作用的ceRNA,呈现出潜在的治疗标.
- 了解EZH2的ceRNA功能对于推进临床癌症治疗至关重要.
研究的目的:
- 进行对经过实验验证的ceRNA轴涉及人类癌症中EZH2的范围审查.
- 识别和分类参与这些轴的RNA类型 (miRNAs, lncRNAs, mRNAs, circRNAs).
- 突出经常观察到的ceRNA轴及其组件,以实现潜在的治疗向.
主要方法:
- 在多个在线数据库中系统搜索相关研究.
- 仅包括涉及EZH2.2的实验验证的ceRNA轴.
- 识别的RNA分子及其相互作用的数据提取和分类.
主要成果:
- 确定了66个独特的ceRNA轴,涉及EZH2.
- 编目了30个微RNA (miRNA),32个长非编码RNA (lncRNA),9个信使RNA (mRNA) 和14个循环RNA (circRNA).
- 在多种癌症类型中观察到类似SPRY4-IT1-miR-101-3p-EZH2和XIST-miR-101-3p-EZH2的重复性轴. 常见的竞争对手包括miR-101-3p,miR-144-3p,miR-124-3p,SPRY4-IT1,XIST,SNHG6,HOXA11-AS,MALAT1和TUG1.1等,这些竞争对手也经常出现.
结论:
- 含有EZH2的ceRNA轴是多样化的,在人类癌症中普遍存在.
- 这些轴代表了新型癌症治疗的有希望的目标.
- 需要进一步的研究来阐明这些ceRNA网络的确切作用和临床适用性.
相关概念视频
02:28Leaky Scanning
5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:55The Nucleolus
9.2K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
9.2K
03:18Non-LTR Retrotransposons
11.9K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.9K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
02:39lncRNA - Long Non-coding RNAs
9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K